Safety and effectiveness of HAART in tuberculosis-HIV co-infected patients in Brazil

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 2, 2013, Pages

  Dos Santos, Ana Paula Gomes ^a   Pacheco, A G ^b   Staviack, A ^a   Golub, J E ^c   Chaisson, R E ^c   Rolla, V C ^b   Kritski, A L ^a   Passos, S R L ^b   De Queiroz Mello, F C ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adverse events; AIDS; HAART; Survival; Tuberculosis

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; ETHAMBUTOL; INDINAVIR; ISONIAZID; LOPINAVIR; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; TUBERCULOSTATIC AGENT;

ADULT; ADVERSE DRUG REACTION; ARTICLE; BIVARIATE ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; SURVIVAL TIME; TUBERCULOSIS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; BRAZIL; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84872278833     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0831     Document Type: Article

References (36)

1. World Health Organization. WHO report 2010. Global Tuberculosis Control 2010. WHO/HTM/TB/2010.7. Geneva, Switzerland: WHO, 2011. http://www.doh.state. fl.us/disease-ctrl/tb/Trends-Stats/Fact-Sheets/US-Global/WHO- Report2010-Global-TB-Control.pdf
2. Kwam C K, Ernst J D. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev 2011; 24: 351-376.
3. Miranda A, Morgan M, Jamal L, et al. Impact of antiretroviral therapy on the incidence of tuberculosis, 1995-2001. PLoS ONE 2007; 9: 1-9.
4. Santoro-Lopes G, Pinho A M F, Harrison L H, et al. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus treated with highly active antiretroviral therapy. Clin Infec Dis 2002; 34: 543-546. (Pubitemid 34112278)
5. Mukadi Y D, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence population in sub-Saharan Africa. AIDS 2001; 13: 143-152. (Pubitemid 32142288)
6. Dean G L, Edwards S G, Ives N J, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16: 75-83. (Pubitemid 34062184)
7. Manabe Y C, Campbell J C, Sydnor E, et al. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr 2007; 46: 456-462. (Pubitemid 350098697)
8. McIlleron H, Meintjes G, Burman W J, et al. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007; 196 (Suppl 1): S63-S75. (Pubitemid 47206086)
9. Ministério da Saúde do Brasil. Boletim Epidemioló gico AIDS e DST 2007. Brasilia, Brazil: Ministério da Saúde do Brasil, 2008. http://www.aids.gov.br Accessed October 2012. [Portuguese]
10. Pozniak A L, Miller R, Ormerod P. The treatment of tuberculosis in HIV-infected persons. AIDS 1999; 13: 435-445.
11. Rolla V C, Vieira M A S, Pinto D P, et al. Safety, efficacy and pharmacokinetics of ritonavir 400 mg /saquinavir 400 mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis. Clin Drug Invest 2006; 26: 469-479.
12. Pedral-Sampaio D B, Alves C R, Netto E M, et al. Efficacy and safety of efavirenz in HIV patients on rifampin for tuberculosis. Braz J Infec Dis 2004; 8: 211-216.
13. Burman W J, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis 1999; 28: 419-430. (Pubitemid 29242513)
14. Kwara A, Flanigan T P, Carter E J. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. Int J Tuberc Lung Dis 2005; 9: 248-257. (Pubitemid 40392938)
15. Piscitelli S C, Flexner C, Minor J R, et al. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 685-693. (Pubitemid 26331107)
16. Breen R A M, Miller R F, Gorsuch T, et al. Virological response to highly active antiretroviral therapy is unaffected by anti-tuberculosis therapy. J Infect Dis 2006; 193: 1437-1440. (Pubitemid 43673392)
17. Dheda K, Lampe F C, Johnson M A, et al. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190: 1670-1676. (Pubitemid 39411018)
18. Girardi E, Palmieri F, Cingolani A, et al. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26: 326-331. (Pubitemid 32435996)
19. Karim S S A, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
20. Franke M F, Robins J M, Mugabo J, et al. Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study. PLoS Med 2011; 8: 1-9.
21. Ministério da Saúde. Tuberculose: guia de vigilância epidemiológica. 1st ed. Brasília, DF, Brazil: Fundaçã o Nacional de Saúde, Ministério da Saúde, 2002. [Portuguese]
22. Greenberg S D, Frager D, Suster B, et al. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology 1994; 193: 115-119. (Pubitemid 24298009)
23. Mello F C Q, Lacerda A P M, Gounder C, et al. The impact of institution of HAART in the co-infection tuberculosis and HIV in a reference hospital for AIDS in Rio de Janeiro, Brazil. Am J Respir Crit Care Med 2001; 163: A496.
24. Hung C C, Chen M Y, Hsiao C F, et al. Improved outcomes of HIV-1 infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS 2003; 17: 2615-2622.
25. Nahid P, Gonzalez L C, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175: 1199-1206. (Pubitemid 46855463)
26. Straetemans M, Bierrenbach A L, Naegelkere N, et al. The effect of tuberculosis on mortality in HIV positive people: a meta analysis. PLoS ONE 2010; 5: 1-10.
27. Small P M, Schecter G F, Goodman P C, et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991; 324: 289-294.
28. Johnson J L, Okwera A, Nsubuga P, et al. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Int J Tuberc Lung Dis 2000; 4: 1032-1040.
29. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg /day versus efavirenz 800 mg /day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006; 20: 131-132. (Pubitemid 41818129)
30. Patel A, Patel K, Patel J, et al. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naïve patients in India who are co-infected with tuberculosis and HIV-1. J Aquir Immune Defic Syndr 2004; 37: 1166-1169. (Pubitemid 39166652)
31. Secretaria de Vigilância em Saúde, Programa Nacional de DST e AIDS. Ministério da Saúde. Recomendações para terapia anti-retroviral em adultos infectados pelo HIV 2007/2008: documento preliminar. Brasilia, Brazil: Secretaria de Vigilância em Saúde, 2008. http://www.aids.gov.br Accessed October 2012. [Portuguese]
32. Schiffer J T, Sterling T R. Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr 2007; 44: 229-234. (Pubitemid 46292227)
33. Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS 2003; 17: 541-545. (Pubitemid 36293107)
34. Bedell R, Heath K V, Hogg R S, et al. Total lymphocyte count as a surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings. Antivir Ther 2003; 8: 379-384. (Pubitemid 37351555)
35. Liu F R, Guo F, Ye J J, et al. Correlation analysis on total lymphocyte count and CD4 count of HIV-infected patients. Int J Clin Pract 2008; 62: 955-960. (Pubitemid 351691484)
36. Mahajan A P, Hogan J W, Snyder B, et al. Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings. J Acquir Immune Defic Syndr 2004; 36: 567-575. (Pubitemid 38544505)